NATCO introdces the Anti-Cancer revolution for the first time. \"VEENAT\" - The Victory in cancer without collateral damage. VEENAT Imatinib 100 mg (as mesylate) Capsules

VEENAT (Imatinib Mesylate) is not offered for sale in UK and other countries where this product is protected with a valid patent.Veenat is offered only to the patients supported by a doctor\'s prescription

The FIRST Target Specific Signal Transduction Inhibitor Tailor -made to select the genetic target Spares the normal Cells. Significantly more-effective in treating CML than conventional therapies. Quick response & improved survival. Less side effects.  USFDA Approved First line treatment in CML - Chronic Meyloid Leukemia

For more information please contact orwriteto:VeenatInformationCellNATCOPharma Limited NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad - 500 033, India Phone No.: +91-40-23547532 Fax No.: +91-40-23548243 

veenat英文说明

Paediatric Use The safety and effectiveness of imatinib in paediatric patients have not been established.

Geriatric Use

In the CML clinical studies, approximately 40% of patients were older than 60 years and 10% were older than 70 years. No difference was observed in the safety profile in patients older than 65 years as compared to younger patients, with the exception of a higher frequency of edema. The efficacy of imatinib was similar in older and younger patients.

In the GIST study, 29% of patients were older than 60 years and 10% of patients were older than 70 years. No obvious differences in the safety or efficacy profile were noted in patients older than of patients does not allow a formal analysis.

ADVERSE REACTIONS

Chronic Myeloid Leukemia

The majority of imatinib treated patients experienced adverse events at some time. Most events were of mild to moderate grade, but drug was discontinuedforadverse events in 2% of patients in chronic phase, 3% in accelerated phase and 5% in blast crisis.

The most frequently reported drug-related adverse events were nausea, vomiting, diarrhoea, edema, and muscle cramps.

Hematologic Toxicity
Cytopenias, and particularly neutropenia and thrombocytopenia, were a consistent finding in all studies, with a higher frequency at doses ≥ 750 mg. The occurrence of cytopenias in CML patients was also dependent on the stage of the disease, with a frequency of grade 3 or 4 neutropenia and thrombocytopenia between 2 and 3-fold higher in blast crisis and accelerated phase compared to chronic phase.

Hepatotoxicity
Severe elevation of transaminases or bilirubin occurred in 1-4% and were usually managed with dose reduction or interruption (the median durationoftheseepisodes was approximately one week). Treatment was discontinued permanently because of liver laboratory abnormalities in less than 0.5% of patients. However,onepatient, who was taking acetaminophen regularly for fever, died of acute liver failure.

OVERDOSAGE
Experience with doses greater than 800 mg is limited. In the event of overdosage, the patient should be observed and appropriate supportive treatment given. An oral dose of 1200 mg/m2/day, approximately 2.5 times the human dose of 800 mg, based on body surface area, was not lethal to ratsollowing14daysofadministration. A dose of 3600 mg/m2/day, approximately 7.5 times the human dose of 800 mg. Was lethal to rats after 7-10 administrations, due to general deterioration of the animals with secondary degenerative histological changes in many tissues.

DOSAGE AND ADMINISTRATION
Therapy should be initiated by a physician experienced in the treatment of patients with chronic myeloid leukemia.

The prescrilbed dose should be administered orally, with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day.

Treatment may be continued as long as there is no evidence of progressivedisease or unacceptable toxicity.

The recommended dosage of imatinib is 400 mg/day for patients in chronic phase CML and 600 mg/day for patients in accelerated phase or blast crisis.

In CML, dose increase from 400 mg to 600 mg in patients withchronicphasedisease, or from 600 mg to 800 mg (given as 400 mg twice daily) in patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory hematologic response after at least 3 months of treatment; loss of a previously achieved hematologic response.

HOW SUPPLOED
Each hard gelatin capsule contains 100 mg of lmatinib as lmatinib Mesylate.

100 mg Capsules

120 capsules in container/60 capsules in container/blister pack of 10 capsules.

Storage
Do not store above 300C. Store in the original pack.

 Keep out of reach and sight of children.

Made in lndia by: NATCO

PHARMA LIMITED, KOTHUR-509 228.

Regd. Office: NATCO HOUSE, ROAD NO.2,

BANJARA HILLS, HYDERABAD-500 033.

本页内容仅方便患者信息流通，据印度公司提供的信息，每个imatinib mesylate（甲磺酸伊马替尼）硬胶囊含100mg的imatinib（伊马替尼）。 1板有10个胶囊，每盒有120个胶囊,零售价价格大约1600元人民币.